NIH has denied the request from Essential Inventions, Inc. to exercise march-in rights under The Bayh-Dole Act in connection with the pricing of Norvir, marketed by Abbott Laboratories for the treatment of patients with HIV/AIDS. The decision and related materials are available online.
Click here to view
Andrew Neighbour, a member of the COGR Board of Directors, delivered testimony at the NIH on march-in rights.
Click here to view